Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes |
| |
| Authors: | Harveshp Mogal Konstantinos Chouliaras Edward A. Levine Perry Shen Konstantinos I. Votanopoulos |
| |
| Affiliation: | Division of Surgical Oncology, Department of General Surgery, Wake Forest University, Winston-Salem, NC, USA |
| |
| Abstract: | Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment option in selected patients with peritoneal dissemination from a variety of epithelial primaries. Even though a small proportion will be alive and potentially cured at 10 years, the majority will eventually develop recurrent disease. Repeat CRS/HIPEC is a valid consideration in a selected subpopulation of patients with isolated peritoneal recurrence. This review summarizes the data on patient selection, feasibility, limitations and outcomes of repeat CRS/HIPEC. |
| |
| Keywords: | Repeat cytoreduction hyperthermic intraperitoneal chemotherapy (HIPEC) |
|
|
